BioPharm Insight Ranks WilmerHale Among Top Three Firms for Licensing and M&A

Download IconDownload Print IconPrint

BioPharm Insight Ranks WilmerHale Among Top Three Firms for Licensing and M&A

Firm News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
For companies in the life sciences sphere, licensing intellectual property and establishing strategic alliances are critical. WilmerHale’s experienced licensing lawyers shepherd biotech, pharmaceutical, healthcare and medical device clients of all sizes through the complex transactions that make their businesses possible, including a broad range of licensing, collaboration, strategic alliance and joint venture agreements. Our attorneys also excel at brokering manufacturing and supply agreements, contract research and development agreements, distribution and commercialization services agreements, and material transfer and confidentiality agreements. They also frequently represent life sciences clients as they license patents—often the foundations of their companies—from, and sponsor research at, leading academic institutions across the United States and Europe. Backed not only by their own experience but also the deep well of knowledge possessed by the firm’s patent, tax, antitrust and EU competition lawyers, our transactional attorneys are ready to handle even the most multifaceted matters. Our team helps clients protect their innovations, forge strategic alliances, and successfully navigate a complex, dynamic industry.

WilmerHale boasts a strong showing in BioPharm Insight’s newly released 2011 year-end league tables—which rank legal counsel activity for licensing agreements and M&A in the biotechnology and pharmaceutical sector—as the only firm ranked among the top three firms globally for licensing transactions based on volume and on value, as well as for M&A in North America based on volume. The firm also placed among the top four firms for M&A deals globally based on volume.

BioPharm Insight’s 2011 league tables highlight the firm’s stellar year, during which the firm represented life sciences clients in deals having an aggregate value of more than $18 billion. Over the course of 2011, WilmerHale’s lawyers:

  • counselled life sciences clients on licensing deals and strategic alliances having a total value of more than $3.73 billion;
  • handled public equity offerings for life sciences clients raising more than $680 million and debt offerings for life sciences clients raising more than $5.03 billion;
  • represented various life sciences clients in M&A transactions worth close to $8 billion;
  • represented life sciences issuers in private financings raising a total of $409 million, and investors in private financings raising a total of $263 million.

WilmerHale’s Life Sciences Group is off to a strong start in 2012, having represented:

  • Verastem in its $62 million initial public offering;
  • Alnylam in its $92 million public offering;
  • Stromedix in its pending acquisition by Biogen Idec for a price of $75 million plus an additional $487.5 million in contingent payments; and
  • Constellation Pharmaceuticals in its strategic collaboration with Genentech, in which Genentech committed funds of $95 million.

Click here to learn more about WilmerHale’s life sciences capabilities and recent work, and here to learn more about BioPharm Insight.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel